AbbVie Inc.
ABBVHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AbbVie Inc. focuses on Drug Manufacturers - General services and products. AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. With a market capitalization of $504.76B, it sits in mega-cap territory. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Market Cap
$504.76B
Beta
0.23
P/E (TTM)
80.69
P/E (Fwd)
17.64
EPS (TTM)
$3.54
EPS (Fwd)
$16.19
ROE
—
ROA
10.5%
Cash
$6.57B
Total Debt
$70.88B
Free CF
$16.87B
52W Change
25.3%
Annual Financials
Cash vs Debt
Where ABBV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ABBV finished 20.29% above its 150-day moving average ($234.99) and 22.33% above its 200-day moving average ($231.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABBV overbought or oversold?
At the October 20, 2026 close, ABBV's RSI(14) was 72.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $6.57B in cash, though total debt stands at $70.88B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $16.87B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on assets of 10.5% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $56.20B (2021) to $61.16B (2025).
The relatively low beta of 0.23 suggests ABBV is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AbbVie Inc. and its sector.